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Abstract: Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by 
nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes 
based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of 
both subtypes is the same, with treatment goal of reducing the number of bowel movements 
and improving consistency. First-line treatment involves counseling the patient about decreasing 
their risk factors, like discontinuing smoking and avoiding medications with suspected associa-
tion such as NSAIDs,  proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for 
immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide 
is considered first-line treatment for MC given its favorable side effect profile and good efficacy, 
though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to 
take budesonide. In glucocorticoid refractory disease, medications that have been tried include 
cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodula-
tors, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation 
of a systematic stepwise approach for relapsing and refractory disease.
Keywords: microscopic colitis, diarrhea, collagenous colitis, lymphocytic colitis, management, 
inflammatory colitis
Introduction
Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by 
nonbloody diarrhea in the setting of normal appearing colonic mucosa and distinct 
histopathologic features. It has a preponderance for middle-aged women and is associ-
ated with various autoimmune disorders, as well as widely used medications includ-
ing NSAIDs.1 MC has two main subtypes, collagenous colitis (CC) and lymphocytic 
colitis (LC), as well as an incomplete variant. Although MC has been well-described 
in the medical literature since the 1970s, many aspects of this disease remain poorly 
understood and few high-quality studies are available to guide therapy. There have 
been promising advancements in the understanding of MC, as several international 
medical societies have published recent statements and guidelines on the diagnosis 
and treatment of MC, and various studies are on the horizon exploring new therapies 
such as novel biologics and even fecal transplant.2,3
General overview
Epidemiology
Based on a recent meta-analysis, the annual overall incidence of CC is 4.14 per 100,000 
person-years and 4.85 per 100,000 person-years for LC. The overall prevalence of CC 
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is 49.21 cases per 100,000 person-years and 63.05 cases per 
100,000 person-years for LC.4 It is important to note that 
most of the data about the incidence and prevalence of MC 
are from the developed Western world, namely the USA, 
Canada, Spain, the Netherlands, and Denmark. Data from 
the developing world are lacking. Age increases the risk of 
MC with an OR of 8.3 for age >65 years compared with 
<65 years.5,6 The incidence is higher in women than in men, 
with a female-to-male incidence ratio of 3.05 for CC and 
1.92 for LC.4
Risk factors
While the etiology of MC is still unknown, various indepen-
dent risk factors, broadly including medications, tobacco, 
and autoimmune conditions, have been identified, which 
are implicated in both developing and flaring of MC. The 
widely used medications include proton pump inhibitors, 
NSAIDs, beta-blockers, statins, and selective serotonin 
reuptake inhibitors.7 In fact, a recent Danish case–control 
study of 10,652 patients found a strong association of pro-
ton pump inhibitors with both CC (OR 6.98) and LC (OR 
3.95), with the strongest association being with the current 
use of lansoprazole.8 In addition to the classically described 
medications thought to have association with MC, new 
medications, namely novel chemotherapeutic agents immune 
checkpoint inhibitors (ICPIs), have been implicated in caus-
ing histologically proven MC. It is important to distinguish 
this entity as patients on ICPIs had a more aggressive course 
often requiring hospitalization and were treated with more 
aggressive immunosuppression such as oral and intravenous 
corticosteroids and infliximab as well as vedolizumab.9 While 
medications are classically thought of as being causative for 
MC, evidence to this fact remains present only in certain 
individual cases with larger scale studies unable to replicate 
the cause and effect relationship.10 Smoking has also been 
found to have an association with MC, leading to the onset 
of disease >10 years earlier than seen in nonsmokers.11 Vari-
ous autoimmune disorders, including celiac disease, type 1 
diabetes, autoimmune thyroiditis, and inflammatory arthritis, 
are also associated with greater risk of MC.7 In fact, patients 
with celiac disease have a 70-fold risk of developing MC over 
the general population, thought to be due to association with 
the human leukocyte antigen-DR3-DQ2, which is prevalent 
in both MC and celiac disease.12,13 Lastly, other lymphocytic 
disorders of the gastrointestinal tract, such as lymphocytic 
gastritis, lymphocytic esophagitis, and duodenal intraepi-
thelial lymphocytosis, have also been associated with MC.14
Pathophysiology
The exact mechanism of diarrhea in MC remains largely 
unknown but is thought to be multifactorial. Mucosal inflam-
mation has been proposed as the most pathophysiologic 
mechanism of the diarrhea. This may be due to mucosal 
changes due to inflammation that lead to reduced sodium and 
chloride absorption, inhibition of the chloride/bicarbonate 
exchange channels, and a decrease in passive permeability.15 
These changes consequently lead to a secretory diarrhea. An 
osmotic element has also been studied and is supported by 
the finding that periods of fasting decrease fecal weight.16 
Bile salt malabsorption may also play a factor, as bile acid 
sequestrants have successfully been used to treat diarrhea 
in MC. In one study, a selenium-labeled homocholic acid 
taurine test was used to study bile acid malabsorption in 
patients with CC, and 44% (12/27) were found to have an 
abnormal test.17 Mucosal injury from luminal contents has 
also been proposed as another factor leading to diarrhea. This 
was evidenced by studying patients who underwent diverting 
ileostomy, who were found to have histologic improvement of 
the MC. This improvement later reverted when the ileostomy 
was reversed.18 The microbiome has also been implicated in 
the pathogenesis of MC, with an identified increase in the 
proinflammatory sulfur-reducing bacterial family Desul-
fovibrionales and a decrease in Coriobacteriaceae, which 
is seen in abundance in the healthy gastrointestinal tract.19 
Additionally, given that the disease is most prevalent in 
postmenopausal women, hormones are thought to play a 
role in the pathophysiology of MC. In a pooled analysis by 
the Nurses’ Health Study, exogenous oral contraceptive and 
menopausal hormone therapy use were associated with the 
increased risk of MC, thereby implicating estrogen in playing 
a role in inflammation of the gastrointestinal tract.20
Symptoms
The hallmark symptom of MC is chronic, nonbloody, watery 
diarrhea. The diarrhea can develop suddenly, or develop 
progressively, to a frequency reported up to 15 times a day. 
The watery diarrhea is often associated with abdominal pain, 
urgency, incontinence, nocturnal symptoms, and/or weight 
loss.6,21 Fatigue has also been noted to be a prevalent symptom 
in MC, as reported by both Nyhlin et al and Kane et al.22,23 
Fatigue severity was associated with concurrent anxiety, 
depression, and somatization in MC.23 While a recent system-
atic review and meta-analysis showed that one in three patients 
with MC can have symptoms of irritable bowel syndrome, 
namely alterations in bowel habits and  abdominal pain, the 
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rate of symptoms was similar to the general population, despite 
recent case–control studies showing the opposite.24 Given over-
lap with various other gastrointestinal illnesses, the diagnosis 
can often be difficult to pinpoint and as such, the differential 
diagnosis for MC is broad, including irritable bowel syndrome 
with diarrhea, medication-induced diarrhea, inflammatory 
bowel disease, and an array of malabsorptive disorders.
Diagnosis
Once MC is suspected, the patient is sent for endoscopic 
evaluation with biopsies, and the diagnosis is ultimately 
made via characteristic histologic findings. While there can 
be laboratory abnormalities that can occur in up to 50% of 
patients with MC, including elevated erythrocyte sedimen-
tation rate and autoantibodies such as antinuclear antibody, 
rheumatoid factor, antimitochondrial antibody, antineutro-
philic cytoplasmic antibodies, anti-Saccharomyces cerevisiae 
antibodies, and antithyroid peroxidase antibodies, these 
are neither sensitive nor specific to the disease and are not 
necessary for diagnosis.6,25 Similar to laboratory evaluation, 
fecal biomarkers such as calprotectin and lactoferrin are of 
little utility for diagnosing MC. While calprotectin levels 
were found to be increased in active vs quiescent disease, 
38% of patients in the study with active MC had negative 
calprotectin levels.26 Fecal lactoferrin fared worse, with only 
3 of 39 patients evaluated having a positive test result in one 
study, and 1 of 21 patients in another.26,27 Colonoscopy usually 
reveals normal colonic mucosa on endoscopic examination. 
The American Society of Gastrointestinal Endoscopy recom-
mends two or more biopsies of the transverse, sigmoid, and 
descending colon if flexible sigmoidoscopy is performed and 
two of more biopsies of the right, transverse, descending, and 
sigmoid colon if colonoscopy is performed.28 We recommend 
that colonoscopy, rather than flexible sigmoidoscopy, be rou-
tinely performed if MC is suspected as histologic changes 
can be patchy in distribution, and inflammatory severity is 
greatest in the more proximal colon. Flexible sigmoidoscopy, 
however, can diagnose >90% of MC.29,30 Classic histologic 
features of LC include >20 intraepithelial lymphocytes per 
100 epithelial cells. Histologic features of CC include a 10–20 
µm diameter of thickened subepithelial collagen band, detach-
ment of surface epithelial cells from subepithelial collagen, 
and an increase in intraepithelial lymphocytes however not 
to the same extent as of LC and not essential to histologic 
diagnosis.31 The histology of incomplete MC, which seeks 
to widen the catchment of symptomatic patients who may 
not classically fit into the diagnostic criteria above, includes 
>10 and <20 intraepithelial lymphocytes for iLC and >5 and 
<10 µm thickness of the collagen band for iCC.32
Prognosis
While the diagnosis of MC does not alter mortality or longev-
ity, it certainly impacts the quality of life. A Spanish study 
evaluating the natural history of MC with a median follow-up 
time of 8 years showed that 75% of patients achieved remis-
sion free from drugs for more than a year. However, while 
93% of patients who achieved remission spontaneously went 
on to have sustained remission, only 60.5% of patients who 
achieved drug-induced remission remained disease free after a 
year.33 Additionally, despite being in clinical remission, patients 
can often have lasting symptoms including abdominal pain, 
fatigue, arthralgia, or myalgia, several years after diagnosis 
compared with controls.22 While MC can have a lasting impact 
on the health-related quality of life (HRQOL) of patients, it is 
important to note that it is not associated with an increased risk 
of colorectal cancer. In fact, patients with MC had a negative 
association with neoplastic polyps compared with patients 
who had chronic diarrhea without MC, with an OR =0.22.34
Management
The overall goal in the management of MC is symptomatic 
improvement, the exact definition of which varies greatly 
between studies. A large population-based study has defined 
clinical remission as improvement in bowel movements to 
less than three per day or less than one watery stool daily over 
the course of 1 week.1,2,35 This has been shown to correlate 
significantly with an increase in HRQOL and consequently 
has been widely utilized. It is yet unclear whether histologic 
remission should be a goal that drives therapy.36,37 Given that, 
to date, no biomarker has been identified to assess the sever-
ity of disease, defining disease activity by clinical variables 
is crucial. The Microscopic Colitis Disease Activity Index 
was developed recently to help further define management 
goals. It is the first prospective study to identify disease activ-
ity and to name six variables (unformed stools, nocturnal 
stools, abdominal pain, weight loss, fecal urgency, and fecal 
incontinence), which they showed to correlate significantly 
with quality of life. The study, which included 162 patients, 
hopes to standardize guidelines for remission and offer a 
more direct comparison of available therapies.21,38 Lastly, 
there is currently discussion regarding including histologic 
remission as a potential end point of therapy.39
We have provided an algorithmic approach to the thera-
peutic management of MC below (Figure 1).
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Lifestyle modifications and symptom 
management
MC has very clearly defined risk factors, including smoking 
and various medications. Lifestyle modifications including 
decreasing caffeine, dairy (in patients with lactose intoler-
ance), and alcohol consumption may improve the diarrhea 
seen in MC.39 It is also critical that concomitant celiac disease 
and bile acid malabsorption be appropriately diagnosed and 
managed, as they can be associated with MC.40
Withdrawal of medications that have been implicated in 
causing MC may be considered as an addition to the stan-
dard first-line therapy. The medications with the strongest 
known association are acarbose, aspirin, NSAIDs, proton 
pump inhibitors (lansoprazole and omeprazole), ranitidine, 
Figure 1 Therapeutic management algorithm for microscopic colitis.
Microscopic colitis
Lifestyle modifications: smoking cessation, medication
review
Budesonide 9 mg daily for 8 weeks ± consider
loperamide for initial symptom control
Responsive Refractory/intolerant
Consider workup of other causes of persistent
diarrhea, ie, celiac disease
Cholestyramine
Bismuth salicylate
Symptom recurrence?
No
Cure
No Yes
Yes
Resume budesonide
Dose >6 mg/day
Maintenance for 12 months Follow refractory/intolerant pathway Fecal transplantSurgery
Immunomodulators (Azathioprine
or 6-MP)
Biologics (infliximab, vedolizumab)
–4.5 mg/day for 12 months
–9 mg/day with taper to lowest effective dose
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 sertraline, and ticlopidine.39,41 In a true case of a drug-induced 
MC, clinical and histologic improvement as well as recur-
rence with rechallenge should be documented.42
Loperamide was until recently the only identified therapy 
for MC. It continues to have a role in symptomatic manage-
ment with doses of 2–16 mg/day according to retrospective 
studies.40 It is important to note that clinical remission is 
seldom achieved in loperamide monotherapy, and there is 
no evidence of histologic improvement.37 No randomized 
placebo-controlled trials have been done to study the use of 
loperamide in MC.
Budesonide
Budesonide is an oral corticosteroid with very low systemic 
bioavailability. This is achieved via the capsule, which is 
formulated to dissolve in a pH-dependent manner to deliver 
the drug into the ileum and ascending colon.43 The 2016 AGA 
clinical guideline for the management of MC recommends 
that budesonide be used as first-line therapy.3 This is based 
on six randomized clinical trials showing clinical response 
and five showing histological response.44–49 This was further 
augmented by a favorable side effect profile as well as the 
ease of once daily dosing, though cost was noted as a bar-
rier to therapy.
A recent 2017 Cochrane review echoed these sentiments 
and demonstrated that budesonide 9 mg/day for 6–8 weeks 
was effective in inducing both clinical and histologic remis-
sion. In two examined studies with a total of 57 patients, 88% 
showed clinical response to budesonide as opposed to 38% 
to placebo and 78% showed histologic response compared 
with 33% with placebo.50 The “number needed to treat” was 
two for CC and three for LC. Notably, the median time to 
remission was ~10.5 days.51 A recent randomized, placebo-
controlled, multicenter study showed that budesonide 9 mg 
daily induced clinical remission at 8 weeks in 79% of patients 
vs 42% with placebo. Histologic remission was attained in 
68% of budesonide group vs 21% of placebo group.52 Further 
randomized controlled trials have shown that remission can 
be maintained for 6 months, with doses as low as 6 mg/day.42,51 
Skin hematoma, cataracts, and increased blood glucose levels 
have been reported as side effects of budesonide therapy.42
Despite the effectiveness of budesonide, relapse rates 
have been reported at 40%–81% and can occur as soon as 2 
weeks after cessation of therapy.53 Certain factors, such as 
longer duration of symptoms prior to initiation of therapy, age 
over 60 years, and more severe baseline diarrhea, can be fore-
boding.1,41,51,53 A prospective, randomized, placebo-controlled 
study by Münch et al aimed to tackle the high relapse rate by 
examining low-dose (4.5 mg/day) budesonide maintenance 
therapy for 12 months. Remission was maintained at 1 year 
in 61.4% of patients in the budesonide arm vs 16.7% in the 
placebo arm. There were no serious adverse events reported 
with more long-term therapy in this study, and overall side 
effects were reported in 7 out of 44 patients.51 In another study 
by Fernandez-Bañares, 53% of patients had at least one clini-
cal relapse after initial withdrawal of budesonide and were 
either resumed on 9 mg/day and tapered to the lowest effec-
tive dose or resumed at the previous lowest effective dose. 
Twenty-one percent of patients needed a budesonide dose 
>6 mg daily to maintain clinical remission, and the others 
tolerated 3 mg/day or 3 mg every other day for maintenance 
of remission. The authors did note that in long-term use of >6 
mg budesonide daily, consideration for alternative therapies 
such as thiopurines could be considered.54
On the horizon are new studies on the use of beclometha-
sone dipropionate, a synthetic corticosteroid with topical 
colonic release. In an open-label multicenter study of 23 
patients, patients were given beclomethasone 10 mg/day for 
4 weeks, followed by 5 mg/day for 4 weeks. Their symptoms 
were assessed via the Bristol stool scale and a telephone inter-
view. Remission was defined as less than eleven loose stools 
over 7 days. At week 8, 70% of patients were in remission.55 
While beclomethasone does appear to induce remission, a 
2010 trial demonstrated that only 26% of patients (from the 
84% with initial response) maintained clinical remission at 
1 year, bringing its longevity into question.50 While beclo-
methasone dipropionate is promising, it is not available in 
the USA and to date is only in use in Europe.
Systemic corticosteroids
Unlike budesonide, the role of systemic corticosteroids in the 
treatment of MC is limited. The 2016 AGA guideline recom-
mends treatment with prednisone or prednisolone only when 
no other treatment is available or when cost is a significant 
hindrance.3 Most of the evidence for the use of systemic cor-
ticosteroids is inferred from the successes of budesonide as 
well as their long-standing use in medical practice, however, 
is considerably limited by their side effect profile. One small 
randomized trial of 12 patients showed a 22% response rate 
in the prednisone arm vs no response in the three patients 
in the control arm.56 A population-based study in 2013 by 
Gentile et al found that the response to prednisolone was 
52.9% (as compared to 82.5 with budesonide) and the rate 
of recurrent disease was higher than with budesonide therapy 
(HR 0.38, CI 0.18–0.85, P=0.02).57 A double-blind, placebo-
controlled randomized trial of 50 mg/day of prednisolone 
 
Cl
in
ica
l a
nd
 E
xp
er
im
en
ta
l G
as
tro
en
te
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
18
9.
22
8.
13
9 
on
 1
0-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical and Experimental Gastroenterology 2019:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
116
Shor et al
for CC showed incomplete remission in two of nine patients 
treated.58 Overall, there is a paucity of evidence for systemic 
corticosteroids in the treatment of MC, and its effects are 
marginal compared with budesonide.39
Refractory  MC
Bismuth salicylate
Bismuth salicylate is recommended by the 2016 AGA guide-
line as a second-line therapy for MC when budesonide is 
unable to be used, either due to cost or adverse effects.3 This 
is based on a small randomized study of 14 patients which 
showed that all seven of seven patients in the intervention 
arm (eight to nine 262 mg bismuth tablets divided into three 
doses per day for 8 weeks) had clinical response vs none of 
the patients in the placebo arm.59 The study included nine 
patients with CC and five patients with LC. Additionally, 
patients treated with bismuth salicylate had a 3-fold, albeit 
not statistically significant, likelihood of achieving a con-
comitant histologic response. A retrospective study showed 
complete response in 53% of patients and partial response in 
28% of patients taking three tablets (262 mg each) of bismuth 
salicylate three times a day.60 Therapy was noted to be more 
effective in patients with milder symptoms and older patients. 
There has also been a case report of lower dose bismuth sub-
salicylate, two tablets of 262 mg each, three times daily for 1 
month, resulting in clinical and histologic remission.61 While 
there have not been any adverse events related to bismuth 
salicylate treatment and the cost of therapy is relatively low, 
there is potential for neurotoxicity and nephrotoxicity with 
long-term use, and the significant pill burden is a conceivable 
barrier to compliance with therapy.62
Cholestyramine
Cholestyramine is thought to play a role in the treatment of 
MC due to its bile acid-binding capacity, as bile acid mal-
absorption has been thought to play a role in pathogenesis 
of MC; however, it also adheres to bacterial toxins, which 
have been implicated in the pathophysiology of CC.2 In a 
retrospective study of 27 patients with biopsy-proven CC, 
the rate of bile acid malabsorption was noted to be 44%, and 
cholestyramine therapy with 4 g two to three times daily (or 
colestipol 5 g two to three times daily) resulted in clinical 
remission in 11/12 (92%) patients with bile acid malabsorp-
tion compared with 10/15 (67%) without. Ultimately, 21/27 
(78%) patients had improvement with bile acid-binding 
therapy.17 Cholestyramine was also studied as an adjunct 
to mesalamine in a randomized control trial of 41 patients 
and did not show any added benefit.63 Given the significant 
potential for drug–drug interactions and the lack of proven 
benefit, the AGA recommended against combination therapy 
with cholestyramine. No randomized clinical trials have been 
done to elucidate the appropriateness of cholestyramine 
monotherapy in MC. Retrospective studies, however, have 
shown response rates of 59%–65%.6,64
Antibiotics and probiotics
AGA recommends against treatment with Boswellia serrata 
as well as other probiotics. While there has been evidence 
showing some efficacy, including a single randomized con-
trolled trial of 31 patients in which 44% of patients treated 
with Boswellia showed clinical improvement (however, no 
histologic or quality of life improvement) compared with 27% 
of patients treated with placebo, the results were not statisti-
cally significant.65 There is also concern about the lack of 
standardization between preparations of B. serrata.3 Similar 
concerns apply to the wide variety of probiotics available 
on the market at present. A randomized placebo-controlled 
trial of Lactobacillus acidophilus LA-5 and Bifidobacterium 
animalis AB-Cap-10 failed to demonstrate a benefit over pla-
cebo.66 An open-label uncontrolled trial of Escherichia  coli 
strain Nissle 1917 did show improvement in stool frequency 
(64% of patients) and stool consistency (50% of patients).67 A 
randomized open-label trial comparing the probiotic VSL#3 
to mesalamine in 30 patients found that 5/11 (46%) patients 
on VSL#3 compared with 1/13 (8%) patients on mesalamine 
achieved remission.68 While VSL#3 may offer a benefit, 
randomized placebo-controlled trials would be necessary. 
No controlled clinical trials evaluating antibiotic use exist; 
however, metronidazole and erythromycin have been used 
anecdotally with varying success.1 In a large retrospective 
clinical review of 163 patients with CC, the rate of response 
to antibiotics (metronidazole, erythromycin, and penicillin 
G) was noted to be 60%, but there was no mention of con-
comitant treatment, dosing, or relapse rate.6 Another large 
retrospective review of 199 patients with LC found that 23 
patients were given metronidazole with 14 showing clinical 
response (61%), however, six relapsed within 1 month.69
Aminosalicylates
Mesalamine can be considered as an alternative to budenoside 
therapy when the latter is not feasible due to contraindications 
or poor clinical response, despite varying evidence on its suc-
cess.3 Two randomized placebo-controlled trials did not show 
any effect of mesalamine 3 g/day compared with placebo in 
short-term 8-week induction.48,52 As previously mentioned, 
a comparison between mesalamine and  mesalamine plus 
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cholestyramine was undertaken and showed a high remis-
sion rate (85% in LC and 91% in CC) in both treatment 
arms, with the addition of cholestyramine being slightly 
superior.63 Efficacy has otherwise been supported solely by 
observational studies and case series. While the 2016 AGA 
guideline recommends mesalamine as an alternative, the 
European guidelines (Spanish microscopic Colitis Group, 
European Microscopic Colitis Group) do not, as there is a 
clear need for more research on the matter.2,3,37
immunomodulators
Immunomodulators such as azathioprine or 6-MP may have 
a role in the treatment of severe, steroid dependent, or refrac-
tory disease. In one small open study, azathioprine induced 
partial or complete remission in eight of nine patients with 
MC.70 A retrospective study found that the overall response 
rate to thiopurines (azathioprine 2 mg/kg/day) was 41% 
(19/46 patients); however, there were significant side effects 
that often led to withdrawal of therapy including hepatitis, 
pancreatitis, bone marrow suppression, and infection.39,71 A 
recent Mayo Clinic case series treated 49 patients with thio-
purines for 4 months, and a complete response was seen in 
43%, while a partial response was seen in 22%. Thirty-five 
percent of patients experienced adverse events leading to 
cessation of therapy.72
The use of methotrexate in MC has had conflicting results. 
In a study of 19 patients with CC naïve to budesonide treated 
with methotrexate 5–25 mg orally weekly, the median dose 
7.5–10 mg, a complete response was seen in 14 patients and 
a partial response was seen in two patients.73 In another study 
of nine patients with CC treated with methotrexate 15–25 
mg subcutaneously weekly, not a single patient improved 
and four patients experienced adverse events leading to 
cessation of therapy.74 A Mayo Clinic case series examined 
12 patients treated with methotrexate (mix of subcutaneous 
and oral dosing) 25 mg/week, of which 7 (58%) achieved 
complete response, 2 (17%) achieved partial response, and 3 
(25%) had no response.72 Seventy-five percent of the patients 
in the Mayo Clinic cohort, however, were on concomitant 
budesonide therapy, limiting generalizability in the use of 
methotrexate as monotherapy. Given the conflicting reports 
on the efficacy of methotrexate in MC and the potential for 
significant adverse effects, further studies on methotrexate 
should be performed prior to recommending its use.
Calcineurin inhibitors have also been used in the treat-
ment of MC. In one study, two patients were treated with 
calcineurin inhibitors (one with tacrolimus and one with 
cyclosporine), with one patient (tacrolimus) achieving com-
plete response without the use of budesonide.72 As this was 
the only article that included the use of calcineurin inhibi-
tors, we do not recommend their use until more research is 
published.
Pentoxifylline
Pentoxifylline, a xanthine oxidase derivative with anti-tumor 
necrosis factor (TNF)-alpha properties, has been used in 
alcoholic hepatitis and intermittent claudication and may 
play a role in the treatment of MC according to a recent case 
report. Nine patients with MC either refractory to, intolerant 
of, or dependent on budesonide received pentoxifylline 400 
mg three times a day for a median of 3 months. Complete 
response occurred in one patient (11%) and partial response 
occurred in three patients (33%); however, it should be noted 
that the one complete responder was intolerant to budesonide, 
leading the authors to surmise that this therapy could perhaps 
be used in patients intolerant to budesonide or those with a 
contraindication to its use.72
Biologics
Overall, the use of anti-TNF-alpha drugs in MC can be con-
sidered for refractory cases as rescue therapy prior to surgical 
intervention.2 As refractory MC is extremely uncommon, 
there is a lack of evidence on the use of anti-TNF-alpha 
therapy. What little data exist originates from case series 
involving adalimumab and infliximab. One such case series 
of ten patients (six with CC and four with LC) refractory to 
budesonide and immunomodulators prospectively evaluated 
adalimumab and infliximab at standard doses for inducing 
remission in inflammatory bowel disease.2,75 The study found 
that eight of ten patients achieved clinical and histologic 
remission as well as improvement in HRQOL.
The role of vedolizumab in the treatment of MC was 
highlighted in a case report of a 75-year-old woman with 
CC for 4 years who was refractory to budesonide and depen-
dent on steroids. A standard induction dosing regimen was 
undertaken, and the patient experienced significant clinical 
improvement after two infusions, and histologic resolution 
was achieved at 3 months.76 A recent case series of eleven 
cases of refractory MC (nine of eleven failed one immuno-
suppressant, ten of eleven failed at least one anti-TNF agent) 
treated with standard induction and maintenance dosing of 
vedolizumab (300 mg IV at weeks 0, 2, and 6, then every 8 
weeks) observed clinical remission in five of eleven  (45%) 
patients of whom 75% also had histologic remission.77
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Fecal transplant
Due to advances in the understanding of the gut microbiome, 
fecal transplant has become a new therapeutic avenue in 
disease such as Clostridium difficile. Its use in MC (specifi-
cally CC) has been examined in one case report of a patient 
refractory to budesonide who received three fecal transplants 
and achieved remission after the third for 11 months.78 Inter-
estingly, while the patient did ultimately relapse, she was then 
treated with budesonide with good clinical response, an effect 
that was unattainable prior to fecal transplant.
Surgery
The role of surgical management in MC is diminishing with 
considerable improvement and efficacy of available medi-
cal therapy. Nevertheless, it does have a role in severe and 
unresponsive MC.39 Surgical therapy for MC includes ileos-
tomy, subtotal colectomy, and ileal pouch anal anastomosis; 
however, data on this matter remain limited to individual 
reports.41,79,80
Conclusion
MC is a disorder characterized by chronic diarrhea that is 
frequently encountered by gastroenterologists. The inci-
dence and consequently awareness of this disease have been 
increasing. It is crucial to maintain a high index of suspicion 
in specific affected populations presenting with chronic diar-
rhea, particularly middle-aged women and the elderly, and 
to appropriately refer for colonoscopy with biopsy when 
needed. While there are two distinct histologic subtypes of 
MC, namely LC and CC, their clinical features and response 
to therapy do not differ significantly, and therefore, for the 
purposes of diagnosis and management, they can be treated 
as one entity of MC. While lifestyle modifications such as 
smoking cessation as well as a thorough medication review 
to remove potential triggers are beneficial, budesonide has 
been recommended by multiple international societies as the 
first-line therapy for the treatment of MC, replacing previ-
ous symptomatic-based therapies. Despite the high success 
rates with budesonide, there is a risk of relapse. Low-dose 
maintenance budesonide appears to be effective in treating 
relapsing MC, but further data are still needed. Alternative 
therapies have been described in MC, including methotrexate, 
mesalamine, antibiotics, and probiotics, but the limited avail-
able data thus far suggest these are not adequately effective. 
Cholestyramine may have a role in patients with concomitant 
bile acid malabsorption or in addition to mesalamine. The 
challenge arises with severe, budesonide-refractory dis-
ease. These patients may benefit from immunomodulators 
or  anti-TNF-alpha therapy though more data, particularly 
randomized placebo-controlled trials, are necessary. Surgery 
may be considered a last resort in severe disease unresponsive 
to other aforementioned therapies. Lastly, the burgeoning 
field exploring the gut microbiome is on the horizon for 
potential use in budesonide-refractory patients, via fecal 
transplant, to enhance response to standard therapy or as a 
means of therapy in itself.
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